A tailored tetravalent peptide displays dual functions to inhibit amyloid β production and aggregation

[1]  S. Nomura,et al.  Peripheral Aβ acts as a negative modulator of insulin secretion , 2022, Proceedings of the National Academy of Sciences of the United States of America.

[2]  B. Meloni,et al.  Arginine and Arginine-Rich Peptides as Modulators of Protein Aggregation and Cytotoxicity Associated With Alzheimer’s Disease , 2021, Frontiers in Molecular Neuroscience.

[3]  Yan‐Mei Li,et al.  Peptides for disrupting and degrading amyloids. , 2021, Current opinion in chemical biology.

[4]  A. Miyazawa,et al.  Identification of a peptide motif that potently inhibits two functionally distinct subunits of Shiga toxin , 2021, Communications Biology.

[5]  P. Bhadury,et al.  From Small Molecules to Synthesized Polymers: Potential Role in Combating Amyloidogenic Disorders. , 2021, ACS chemical neuroscience.

[6]  S. Funamoto,et al.  A nontoxigenic form of Shiga toxin 2 suppresses the production of amyloid β by altering the intracellular transport of amyloid precursor protein through its receptor-binding B-subunit. , 2021, Biochemical and biophysical research communications.

[7]  Son Tung Ngo,et al.  Amyloid Oligomers: A Joint Experimental/Computational Perspective on Alzheimer's Disease, Parkinson's Disease, Type II Diabetes, and Amyotrophic Lateral Sclerosis. , 2021, Chemical reviews.

[8]  L. Goldstein,et al.  Cholesterol-lowering drugs reduce APP processing to Aβ by inducing APP dimerization , 2020, Molecular biology of the cell.

[9]  S. Funamoto,et al.  Successive cleavage of β-amyloid precursor protein by γ-secretase. , 2020, Seminars in cell & developmental biology.

[10]  J. D. Del Valle,et al.  N-Amino peptide scanning reveals inhibitors of Aβ42 aggregation , 2020, RSC advances.

[11]  S. Engelborghs,et al.  Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer’s disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study , 2020, Alzheimer's Research & Therapy.

[12]  M. Yamashita,et al.  The inducible amphisome isolates viral hemagglutinin and defends against influenza A virus infection , 2020, Nature Communications.

[13]  D. Holtzman,et al.  Alzheimer Disease: An Update on Pathobiology and Treatment Strategies , 2019, Cell.

[14]  W. Tourtellotte,et al.  Axonal organization defects in the hippocampus of adult conditional BACE1 knockout mice , 2018, Science Translational Medicine.

[15]  J. Herms,et al.  BACE1 inhibition more effectively suppresses initiation than progression of β-amyloid pathology , 2018, Acta Neuropathologica.

[16]  G. Schröder,et al.  Fibril structure of amyloid-β(1–42) by cryo–electron microscopy , 2017, Science.

[17]  S. Yamasaki,et al.  Affinity-Based Screening of Tetravalent Peptides Identifies Subtype-Selective Neutralizers of Shiga Toxin 2d, a Highly Virulent Subtype, by Targeting a Unique Amino Acid Involved in Its Receptor Recognition , 2016, Infection and Immunity.

[18]  T. van Groen,et al.  Increase of Positive Net Charge and Conformational Rigidity Enhances the Efficacy of d-Enantiomeric Peptides Designed to Eliminate Cytotoxic Aβ Species. , 2016, ACS chemical neuroscience.

[19]  A. Caflisch,et al.  Specific Inhibition of β-Secretase Processing of the Alzheimer Disease Amyloid Precursor Protein. , 2016, Cell reports.

[20]  K. Nishikawa,et al.  Identification of a Wide Range of Motifs Inhibitory to Shiga Toxin by Affinity-Driven Screening of Customized Divalent Peptides Synthesized on a Membrane , 2014, Applied and Environmental Microbiology.

[21]  S. Itohara,et al.  Single App knock-in mouse models of Alzheimer's disease , 2014, Nature Neuroscience.

[22]  Y. Ihara,et al.  Substrate ectodomain is critical for substrate preference and inhibition of γ-secretase , 2013, Nature Communications.

[23]  D. Friedman,et al.  Faculty Opinions recommendation of Structural conversion of neurotoxic amyloid-beta(1-42) oligomers to fibrils. , 2013 .

[24]  E. Kita,et al.  Identification of a Peptide-Based Neutralizer That Potently Inhibits Both Shiga Toxins 1 and 2 by Targeting Specific Receptor-Binding Regions , 2013, Infection and Immunity.

[25]  V. Šendula-Jengić,et al.  Modulators of γ-Secretase Activity Can Facilitate the Toxic Side-Effects and Pathogenesis of Alzheimer's Disease , 2013, PloS one.

[26]  Charles R. Sanders,et al.  The Amyloid Precursor Protein Has a Flexible Transmembrane Domain and Binds Cholesterol , 2012, Science.

[27]  D. Selkoe,et al.  Biochemistry of amyloid β-protein and amyloid deposits in Alzheimer disease. , 2012, Cold Spring Harbor perspectives in medicine.

[28]  C. Haass,et al.  Trafficking and proteolytic processing of APP. , 2012, Cold Spring Harbor perspectives in medicine.

[29]  T. Bozza,et al.  The Alzheimer's β-secretase enzyme BACE1 is required for accurate axon guidance of olfactory sensory neurons and normal glomerulus formation in the olfactory bulb , 2011, Molecular Neurodegeneration.

[30]  K. Nishikawa.  Recent Progress of Shiga Toxin Neutralizer for Treatment of Infections by Shiga Toxin-Producing Escherichia coli , 2011, Archivum Immunologiae et Therapiae Experimentalis.

[31]  D. Chetkovich,et al.  BACE1-/- mice exhibit seizure activity that does not correlate with sodium channel level or axonal localization , 2010, Molecular Neurodegeneration.

[32]  Judianne Davis,et al.  Structural conversion of neurotoxic amyloid-β(1–42) oligomers to fibrils , 2010, Nature Structural &Molecular Biology.

[33]  S. Constantinescu,et al.  What is the role of amyloid precursor protein dimerization? , 2010, Cell adhesion & migration.

[34]  B. Meier,et al.  Dynamics and Cleavability at the alpha-cleavage site of APP(684-726) in different lipid environments. , 2008, Biophysical journal.

[35]  J. Schulz,et al.  Efficient Inhibition of the Alzheimer's Disease β-Secretase by Membrane Targeting , 2008, Science.

[36]  K. Sakai-Kato,et al.  Racemization of the amyloidal beta Asp1 residue blocks the acceleration of fibril formation caused by racemization of the Asp23 residue. , 2007, Biochemical and biophysical research communications.

[37]  A. Delacourte,et al.  Involvement of β-site APP cleaving enzyme 1 (BACE1) in amyloid precursor protein-mediated enhancement of memory and activity-dependent synaptic plasticity , 2007, Proceedings of the National Academy of Sciences.

[38]  J. Marth,et al.  Beta-galactoside alpha2,6-sialyltransferase I cleavage by BACE1 enhances the sialylation of soluble glycoproteins. A novel regulatory mechanism for alpha2,6-sialylation. , 2007, The Journal of biological chemistry.

[39]  N. Greenfield.  Using circular dichroism spectra to estimate protein secondary structure , 2007, Nature Protocols.

[40]  Michael B Yaffe,et al.  A multivalent peptide library approach identifies a novel Shiga toxin inhibitor that induces aberrant cellular transport of the toxin , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[41]  P. Wong,et al.  Bace1 modulates myelination in the central and peripheral nervous system , 2006, Nature Neuroscience.

[42]  P. Saftig,et al.  Control of Peripheral Nerve Myelination by the ß-Secretase BACE1 , 2006, Science.

[43]  Y. Ihara,et al.  Equimolar production of amyloid beta-protein and amyloid precursor protein intracellular domain from beta-carboxyl-terminal fragment by gamma-secretase. , 2006, The Journal of biological chemistry.

[44]  Ken Hatano,et al.  Identification of the optimal structure required for a Shiga toxin neutralizer with oriented carbohydrates to function in the circulation. , 2005, The Journal of infectious diseases.

[45]  H. Yonekawa,et al.  In vivo cleavage of alpha2,6-sialyltransferase by Alzheimer beta-secretase. , 2005, The Journal of biological chemistry.

[46]  C. Haass.  Take five—BACE and the γ‐secretase quartet conduct Alzheimer's amyloid β‐peptide generation , 2004 .

[47]  C. Haass.  Take five--BACE and the gamma-secretase quartet conduct Alzheimer's amyloid beta-peptide generation. , 2004, The EMBO journal.

[48]  Chisato Yamasaki,et al.  A therapeutic agent with oriented carbohydrates for treatment of infections by Shiga toxin-producing Escherichia coli O157:H7 , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[49]  S. Kitazume,et al.  Alzheimer's β-secretase, β-site amyloid precursor protein-cleaving enzyme, is responsible for cleavage secretion of a Golgi-resident sialyltransferase , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[50]  Raphael Kopan,et al.  Murine Notch Homologs (N1–4) Undergo Presenilin-dependent Proteolysis* , 2001, The Journal of Biological Chemistry.

[51]  T. Bayer,et al.  Homodimerization of Amyloid Precursor Protein and Its Implication in the Amyloidogenic Pathway of Alzheimer's Disease* , 2001, The Journal of Biological Chemistry.

[52]  S. Kitazume,et al.  Alzheimer's beta-secretase, beta-site amyloid precursor protein-cleaving enzyme, is responsible for cleavage secretion of a Golgi-resident sialyltransferase. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[53]  J. Treanor,et al.  Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. , 1999, Science.

[54]  Iva Greenwald,et al.  Presenilin is required for activity and nuclear access of Notch in Drosophila , 1999, Nature.

[55]  C. Masters,et al.  Crystal structure of the N-terminal, growth factor-like domain of Alzheimer amyloid precursor protein , 1999, Nature Structural Biology.

[56]  George M Whitesides,et al.  Polyvalent Interactions in Biological Systems: Implications for Design and Use of Multivalent Ligands and Inhibitors. , 1998, Angewandte Chemie.

[57]  C. Soto,et al.  Inhibition of Alzheimer's amyloidosis by peptides that prevent beta-sheet conformation. , 1996, Biochemical and biophysical research communications.

[58]  D. Selkoe,et al.  The Role of APP Processing and Trafficking Pathways in the Formation of Amyloid β‐Protein a , 1996 .

[59]  D. Selkoe,et al.  The role of APP processing and trafficking pathways in the formation of amyloid beta-protein. , 1996, Annals of the New York Academy of Sciences.

[60]  T. Iwatsubo,et al.  Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific Aβ monoclonals: Evidence that an initially deposited species is Aβ42(43) , 1994, Neuron.

[61]  S. Squazzo,et al.  Evidence that production and release of amyloid beta-protein involves the endocytic pathway. , 1994, The Journal of biological chemistry.

[62]  T. Iwatsubo,et al.  Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). , 1994, Neuron.

[63]  T. Oltersdorf,et al.  Cleavage of amyloid beta peptide during constitutive processing of its precursor. , 1990, Science.

[64]  K. Grzeschik,et al.  The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor , 1987, Nature.

[65]  C. Masters,et al.  Amyloid plaque core protein in Alzheimer disease and Down syndrome. , 1985, Proceedings of the National Academy of Sciences of the United States of America.